{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:36:32Z","timestamp":1790181392458,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Medical Research Council","award":["BH152850"],"award-info":[{"award-number":["BH152850"]}]},{"DOI":"10.13039\/501100002382","name":"King Faisal Specialist Hospital and Research Centre","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100002382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GO2955\/1-1 [FG]"],"award-info":[{"award-number":["GO2955\/1-1 [FG]"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10875-019-00687-4","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T21:22:50Z","timestamp":1568236970000},"page":"776-785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC\/CID Phenotype Responsive to Ruxolitinib"],"prefix":"10.1007","volume":"39","author":[{"given":"Tariq","family":"Al Shehri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Loughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thivytra","family":"Mohanadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Slatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hambleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desa","family":"Lilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"issue":"8","key":"687_CR1","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","volume":"208","author":"L Liu","year":"2011","unstructured":"Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635\u201348.","journal-title":"J Exp Med"},{"issue":"1","key":"687_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1100102","volume":"365","author":"FL van de Veerdonk","year":"2011","unstructured":"van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LAB, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54\u201361.","journal-title":"N Engl J Med"},{"issue":"25","key":"687_CR3","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","volume":"127","author":"J Toubiana","year":"2016","unstructured":"Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154\u201364.","journal-title":"Blood"},{"issue":"4","key":"687_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10875-018-0513-z","volume":"38","author":"AE Smyth","year":"2018","unstructured":"Smyth AE, Kaleviste E, Snow A, Kisand K, McMahon CJ, Cant AJ, et al. Aortic calcification in a patient with a gain-of-function STAT1 mutation. J Clin Immunol. 2018;38(4):468\u201370.","journal-title":"J Clin Immunol"},{"issue":"3","key":"687_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.4049\/jimmunol.1200926","volume":"189","author":"S Takezaki","year":"2012","unstructured":"Takezaki S, Yamada M, Kato M, Park MJ, Maruyama K, Yamazaki Y, et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol. 2012;189(3):1521\u20136.","journal-title":"J Immunol"},{"key":"687_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10875-015-0214-9","volume":"36","author":"M Depner","year":"2016","unstructured":"Depner M, Fuchs S, Raabe J, Frede N, Glocker C, Doffinger R, et al. The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in STAT1. J Clin Immunol. 2016;36:73\u201384.","journal-title":"J Clin Immunol"},{"key":"687_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fimmu.2017.00274","volume":"8","author":"K Meesilpavikkai","year":"2017","unstructured":"Meesilpavikkai K, Dik WA, Schrijver B, et al. A novel heterozygous mutation in the STAT1 SH2 domain causes chronic mucocutaneous candidiasis, atypically diverse infections, autoimmunity, and impaired cytokine regulation. Front Immunol. 2017;8:274.","journal-title":"Front Immunol"},{"issue":"6","key":"687_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10875-018-0536-5","volume":"38","author":"H Al Dhanhani","year":"2018","unstructured":"Al Dhanhani H, Al Shehri T, Lilic D, et al. Double trouble? CMC with a mutation in both AIRE and STAT1. J Clin Immunol. 2018;38(6):635\u20137.","journal-title":"J Clin Immunol"},{"issue":"1","key":"687_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jaci.2015.12.1320","volume":"138","author":"A Sobh","year":"2016","unstructured":"Sobh A, Chou J, Schneider L, Geha RS, Massaad MJ. Chronic mucocutaneous candidiasis associated with an SH2 domain gain-of-function mutation that enhances STAT1 phosphorylation. J Allergy Clin Immunol. 2016;138(1):297\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"687_CR10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.jaci.2017.07.027","volume":"141","author":"EP Sampaio","year":"2018","unstructured":"Sampaio EP, Ding L, Rose SR, Cruz P, Hsu AP, Kashyap A, et al. Novel signal transducer and activator of transcription 1 mutation disrupts small ubiquitin-related modifier conjugation causing gain of function. J Allergy Clin Immunol. 2018;141(5):1844\u20131853 e1842.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"687_CR11","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","volume":"139","author":"KG Weinacht","year":"2017","unstructured":"Weinacht KG, Charbonnier LM, Alroqi F, Plant A, Qiao Q, Wu H, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017;139(5):1629\u20131640 e1622.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"687_CR12","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1002\/eji.201445344","volume":"45","author":"J Zheng","year":"2015","unstructured":"Zheng J, van de Veerdonk FL, Crossland KL, Smeekens SP, Chan CM, al Shehri T, et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur J Immunol. 2015;45(10):2834\u201346.","journal-title":"Eur J Immunol"},{"issue":"9","key":"687_CR13","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/blood-2002-12-3816","volume":"102","author":"D Ungureanu","year":"2003","unstructured":"Ungureanu D, Vanhatupa S, Kotaja N, et al. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood. 2003;102(9):3311\u20133.","journal-title":"Blood"},{"issue":"1","key":"687_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood-2004-11-4514","volume":"106","author":"D Ungureanu","year":"2005","unstructured":"Ungureanu D, Vanhatupa S, Gronholm J, et al. SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood. 2005;106(1):224\u20136.","journal-title":"Blood"},{"issue":"4","key":"687_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1182\/blood-2011-04-347930","volume":"118","author":"A Begitt","year":"2011","unstructured":"Begitt A, Droescher M, Knobeloch KP, Vinkemeier U. SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNgamma. Blood. 2011;118(4):1002\u20137.","journal-title":"Blood"},{"issue":"2","key":"687_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","volume":"135","author":"E Higgins","year":"2015","unstructured":"Higgins E, Al Shehri T, McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"687_CR17","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","volume":"142","author":"LR Forbes","year":"2018","unstructured":"Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"687_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2091-13-20","volume":"13","author":"J Gronholm","year":"2012","unstructured":"Gronholm J, Vanhatupa S, Ungureanu D, et al. Structure-function analysis indicates that sumoylation modulates DNA-binding activity of STAT1. BMC Biochem. 2012;13:20.","journal-title":"BMC Biochem"},{"issue":"6","key":"687_CR19","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaci.2013.01.052","volume":"131","author":"EP Sampaio","year":"2013","unstructured":"Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131(6):1624\u201334.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"687_CR20","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jaci.2012.11.054","volume":"131","author":"G Uzel","year":"2013","unstructured":"Uzel G, Sampaio EP, Lawrence MG, Hsu AP, Hackett M, Dorsey MJ, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol. 2013;131(6):1611\u201323.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"687_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1189\/jlb.0513250","volume":"95","author":"Y Mizoguchi","year":"2014","unstructured":"Mizoguchi Y, Tsumura M, Okada S, Hirata O, Minegishi S, Imai K, et al. Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis. J Leukoc Biol. 2014;95(4):667\u201376.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"687_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10875-018-0557-0","volume":"38","author":"AR Bernasconi","year":"2018","unstructured":"Bernasconi AR, Yancoski J, Villa M, Oleastro MM, Galicchio M, Rossi JG. Increased STAT1 amounts correlate with the phospho-STAT1 level in STAT1 gain-of-function defects. J Clin Immunol. 2018;38(7):745\u20137.","journal-title":"J Clin Immunol"},{"key":"687_CR23","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3389\/fimmu.2019.01433","volume":"10","author":"O Zimmerman","year":"2019","unstructured":"Zimmerman O, Olbrich P, Freeman AF, Rosen LB, Uzel G, Zerbe CS, et al. STAT1 gain-of-function mutations cause high total STAT1 levels with normal dephosphorylation. Front Immunol. 2019;10:1433.","journal-title":"Front Immunol"},{"issue":"4","key":"687_CR24","doi-asserted-by":"publisher","first-page":"ofx202","DOI":"10.1093\/ofid\/ofx202","volume":"4","author":"O Zimmerman","year":"2017","unstructured":"Zimmerman O, Rosler B, Zerbe CS, et al. Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease. Open Forum Infect Dis. 2017;4(4):ofx202.","journal-title":"Open Forum Infect Dis"},{"key":"687_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","volume":"38","author":"M Bloomfield","year":"2018","unstructured":"Bloomfield M, Kanderova V, Parackova Z, et al. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol. 2018;38:589\u2013601.","journal-title":"J Clin Immunol"},{"key":"687_CR26","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.3389\/fimmu.2018.03047","volume":"9","author":"TH Mogensen","year":"2019","unstructured":"Mogensen TH. IRF and STAT transcription factors - from basic biology to roles in infection, protective immunity, and primary immunodeficiencies. Front Immunol. 2019;9:3047.","journal-title":"Front Immunol"},{"issue":"5","key":"687_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2011.09.016","volume":"35","author":"AM Siegel","year":"2011","unstructured":"Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity. 2011;35(5):806\u201318.","journal-title":"Immunity"},{"issue":"1","key":"687_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","volume":"33","author":"AT Virtanen","year":"2019","unstructured":"Virtanen AT, Haikarainen T, Raivola J, et al. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15\u201332.","journal-title":"BioDrugs"},{"key":"687_CR29","doi-asserted-by":"crossref","unstructured":"Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2018:1\u201313.","DOI":"10.1080\/1744666X.2019.1544892"},{"issue":"S1","key":"687_CR30","first-page":"15","volume":"182","author":"T Al Shehri","year":"2015","unstructured":"Al Shehri T, Abinun M, Gennery AR, et al. Is gain-of-function STAT1 CMC an interferonopathy? Clin Exp Immunol. 2015;182(S1):15.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"687_CR31","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201847955","volume":"49","author":"E Kaleviste","year":"2019","unstructured":"Kaleviste E, Saare M, Leahy TR, Bondet V, Duffy D, Mogensen TH, et al. Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined. Eur J Immunol. 2019;49(5):790\u2013800.","journal-title":"Eur J Immunol"},{"key":"687_CR32","doi-asserted-by":"crossref","unstructured":"van de Veerdonk FL, Netea MG. Treatment options for chronic mucocutaneous candidiasis. J Inf Secur 2016:72 Suppl:S56\u2013S60.","DOI":"10.1016\/j.jinf.2016.04.023"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-019-00687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-019-00687-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-019-00687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T18:20:11Z","timestamp":1599762011000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-019-00687-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s10875-019-00687-4","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was granted by the Great North Biobank (GNB), Reference No. 5458\/10\/H0906\/22, and Newcastle Autoimmune Inflammatory Rheumatic Diseases (NAIRD) Research Biobank, Reference No. 10\/H0106\/30.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}